The positive opinion in this setting adds to the recommended use of pembrolizumab in patients with melanoma, non-small-cell lung cancer, classical Hodgkin lymphoma, urothelial cancer, head and neck squamous cell carcinoma, renal cell carcinoma, esophageal or gastroesophageal junction adenocarcinoma, and cancer of the colon or rectum. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

Nearly three-quarters (71.4%) had breast cancer, while the remaining had a diagnosis of colorectal cancer, Hodgkin disease, or non-Hodgkin lymphoma.

The FDA approval follows findings from a clinical trial of 327 patients with these rare non-Hodgkin lymphoma (NHL) forms who had received at least one prior treatment.

This month we bring you a round-up of four trials investigating nivolumab in diverse tumors, including non-small-cell lung cancer, Hodgkin lymphoma, and nasopharyngeal carcinoma. Read on to find out more.

Sixty-nine percent of the study participants had a solid tumor malignancy (most commonly breast, lung, or prostate malignancies), while the remaining 31% of patients had a hematologic malignancy, most commonly leukemia or non-Hodgkin lymphoma.

And indeed, mogamulizumab was recently approved by the US FDA for the treatment of these cutaneous T-cell lymphoma subtypes.

The researchers investigated its safety and activity in a phase I dose-escalation trial among 90 patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, B- and T-cell non-Hodgkin lymphoma, or Hodgkin lymphoma, who had received at least one previous treatment regimen.

Silicone-filled breast implants are associated with a high relative risk for developing anaplastic large-cell lymphoma in the breast, but the absolute risk remains low, confirms a population-based study.

Read more on this decision affecting treatment of some types of large B-cell lymphoma here

medwireNews : The kinase inhibitor acalabrutinib has been approved by the US Food and Drug Administration for the treatment of adults with mantle cell lymphoma who have received at least one prior treatment.

medwireNews : The US FDA has granted accelerated approval for the use of copanlisib for patients with relapsed follicular B-cell non-Hodgkin lymphoma and agreed that men with metastatic castration-resistant prostate cancer may be given a lower dose of cabazitaxel than previously recommended.

Professor Anas Younes tells  medwireNews about the current issues in lymphoma practice, both for the clinician and patients.

The team reviewed neurologic adverse events in 133 adults with refractory B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, or non-Hodgkin lymphoma who underwent lymphodepletion chemotherapy followed by CD19 CAR-T cell infusion.